title: Liver transplantation for HBsAg-positive recipients using grafts from HBsAg-positive deceased donors.
abstract: This study reports our experience using deceased donor liver grafts from HBsAg-positive donors. We performed eight cases of liver transplantation (LT) using grafts from deceased HBsAg-positive donors between November 2005 and October 2010. The median age of donors was 48 years (range: 26-64). HBV DNA in the serum of donors ranged from 44 to 395 IU/ml, but HBeAg in all donors was negative. Preoperative laboratory and liver biopsy samples revealed the absence of definitive cirrhotic features and hepatitis. All recipients showed HBsAg positive preoperatively except one patient with HBsAg(-) status post previous LT for HBV related liver cirrhosis. The median age was 60 years (range: 46-76) at LT. Post-LT antiviral management consisted of hepatitis B immunoglobulin and antiviral nucleos(t)ide analogues. The median follow-up period was 25.5 months (range: 14-82). Of eight recipients, two recipients experienced serum HBsAg and HBV DNA disappearance postoperatively. Three recipients died of HBV-unrelated causes. The remaining five recipients were stable with normal liver function and no marked pathologic changes on follow-up biopsies. This experience shows that LT using grafts from deceased HBsAg-positive donors is feasible, and may represent a valuable expansion of the pool of organ donors with appropriate antiviral management and monitoring.
authors.affiliation: Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: YoungRok
authors.initials: Y
authors.lastname: Choi
authors.forename: Jong Young
authors.initials: JY
authors.lastname: Choi
authors.forename: Nam-Joon
authors.initials: NJ
authors.lastname: Yi
authors.forename: Kyoungbun
authors.initials: K
authors.lastname: Lee
authors.forename: Shozo
authors.initials: S
authors.lastname: Mori
authors.forename: Geun
authors.initials: G
authors.lastname: Hong
authors.forename: Hyeyoung
authors.initials: H
authors.lastname: Kim
authors.forename: Min-Su
authors.initials: MS
authors.lastname: Park
authors.forename: Tae
authors.initials: T
authors.lastname: Yoo
authors.forename: Suk-Won
authors.initials: SW
authors.lastname: Suh
authors.forename: Hae Won
authors.initials: HW
authors.lastname: Lee
authors.forename: Kwang-Woong
authors.initials: KW
authors.lastname: Lee
authors.forename: Kyung-Suk
authors.initials: KS
authors.lastname: Suh
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D007136:Immunoglobulins; D019259:Lamivudine; C413685:entecavir; D006147:Guanine; C045213:hepatitis B hyperimmune globulin
keywords: HBsAg positive; hepatitis B antigen; liver transplantation; marginal graft